Evogene (EVGN) has released an update.
Evogene Ltd. has reported that, aside from the rejected option grants to the CEO, all proposals at the annual shareholders’ meeting on June 13, 2024, were approved. These approvals align with the Israeli Companies Law and Evogene’s articles of association. The meeting’s outcomes have been documented in a report filed with the SEC, which also relates to several of the company’s registration statements.
For further insights into EVGN stock, check out TipRanks’ Stock Analysis page.
